Author Archive

Head office relocation announcement

We are pleased to announce that our head office will relocate to the following address as of April 11, 2018.
Tokyo Park Tower 201, 1-103 Kanda Jinbocho,
Chiyoda-ku, Tokyo 101-0051, JAPAN


Anaeropharma Science announces appointment of new Board Director

Dr. Yoshimatsu has been named the new Board Director of Anaeropharma Science. He started this new role from March 2018. Prior to this, he spent 40 years in leading research activities mainly in the oncology area at Eisai, one of the leading Japanese pharmaceutical companies.


Anaeropharma Science will be presenting its latest research outcomes regarding agonistic antibody producing recombinant Bifidobacterium at the 2018 Annual Meeting of the AACR

Anaeropharma Science will be presenting its latest research outcomes towards agonistic anti-4-1BB scFv antibody producing recombinant Bifidobacterium at the 2018 Annual Meeting of the AACR (American Association for Cancer Research), which takes place from April 14 to 18 in Chicago, the poster is titled Cancer immunotherapy with agonistic anti-4-1BB producing and secreting Bifidobacterium in syngeneic mouse model”, which will be presented on Apr. 16, from 1:00 PM to 5:00 PM, in the session of immune checkpoint 2.


Anaeropharma has presented new research outcomes at AACR Conference on Tumor Immunology and Immunotherapy

At AACR Special Conference on Tumor Immunology and Immunotherapy took place October 1-4, 2017 in Boston, MA, Anaeropharma has presented its new research outcomes regarding cancer immunotherapy titled “Anti-PD-1 antibody scFv producing recombinant Bifidobacterium exerts antitumor effect in a larger fraction of the treated mice comparing to full length anti-PD-1 antibody”.

PDF download here

 


Anaeropharma Science Announces Closing of Financing

TOKYO, July 5, 2017

Anaeropharma Science, Inc., a company dedicated to the development of novel therapeutics to target hypoxic solid tumors, announced on July 5 it has secured US$13.2 million in new capital. The participants in the financing round include three new investors, Novartis, Shinsei Corporate Investment Limited and Seventure Partners’ Health for Life Capital fund, and two existing investors, Innovation Network Corporation of Japan and Mitsubishi UFJ Capital’s managed fund. Anaeropharma will use the financing to accelerate the development of multiple programs based on its proprietary platform technology.

About Anaeropharma Science, Inc.

Anaeropharma is a biopharmaceutical company engaged in research and development of drug candidates that target hypoxic microenvironments of tumors by using recombinant Bifidobacterium. This approach offers broad potential to be more effective to solid tumors and less toxic to healthy tissues than conventional anti-cancer drugs. APS001F, a recombinant Bifidobacterium to express Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is its leading development product which is under a clinical trial in the U.S., and additional programs in the immune oncology area such as immune checkpoint blockers and other immune-related molecules expressing recombinant Bifidobacteria are under active development.

PDF download here


Anaeropharma Science will be presenting its latest research outcomes at the 2017 Annual Meeting of the AACR

Anaeropharma Science will be presenting its latest research outcomes towards combination approaches of its i-DPS therapy with immune checkpoint inhibitor at the 2017 Annual Meeting of the AACR (American Association for Cancer Research), which takes place from April 1st to the 5th in Washington D.C.

The first poster is titled “Synergistic anti-tumor efficacy of combination therapy with APS001F, a cytosine deaminase (CD) expressing Bifidobacterium, 5-fluorocytosine (5-FC) and anti-mPD-1 antibody in syngeneic mice model”, which will be presented on Apr. 4th, from 1:00 PM to 5:00 PM, in the session of Clinical Immunotherapy, Viruses, and Bacteria.

PDF download here

The second one is titled “Enhanced anti-tumor effects by a combination approach of interferon-γ producing recombinant Bifidobacterium and anti-mPD-1 antibody in CT26 syngeneic mouse model”, which will be presented on Apr. 3rd, from 1:00 PM to 5:00 PM, in the session of Checkpoints 2: Small-Molecule Inhibitors.

PDF download here


Anaeropharma will present new research outcomes at AACR Conference on Tumor Immunology and Immunotherapy

At upcoming AACR Special Conference on Tumor Immunology and Immunotherapy taking place October 20-23, 2016 in Boston, MA, Anaeropharma will present its new research outcomes regarding cancer immunotherapy titled “Anti-CTLA-4 antibody scFv producing recombinant Bifidobacterium secretes CTLA-4 blocker specifically inside hypoxic tumor and suppresses tumor growth in syngeneic mice model”.

PDF download here


Anaeropharma has presented at 20th JFCR-ISCC (Japanese Foundation for Cancer Research-International Symposium on Cancer Chemotherapy)

At 20th JFCR-ISCC held in December 2015, Anaeropharma has presented its progress on immune checkpoint blocker producing B. longum which titled in “i-DPS (in situ Delivery and Production System): A “smart” Drug Delivery System to Produce Immune Checkpoint Blockers inside Hypoxic Tumor”.


Anaeropharma has presented at BioJapan2015

Anaeropharma has presented its technology platform at BioJapan2015 held in October.


Anaeropharma has presented at JCA (Japanese Cancer Association) Annual Meeting 2015

Anaeropharma has presented its recent research progress which titled in “In situ Delivery and Production System (i-DPS) of Immune Checkpoint Blockers Targeting Tumor Microenvironment” at the annual meeting of JCA held in October, 2015.